Mauna Kea Technologies Valuation

Is 1MK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1MK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1MK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1MK's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1MK?

Key metric: As 1MK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1MK. This is calculated by dividing 1MK's market cap by their current revenue.
What is 1MK's PS Ratio?
PS Ratio1.4x
Sales€8.16m
Market Cap€11.31m

Price to Sales Ratio vs Peers

How does 1MK's PS Ratio compare to its peers?

The above table shows the PS ratio for 1MK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.6x
GME Geratherm Medical
0.8x1.9%€14.7m
AAQ1 aap Implantate
1.9xn/a€22.0m
AUG Audientes
12.6xn/a€6.9m
MF6 MagForce
3.3x50.9%€3.6m
1MK Mauna Kea Technologies
1.4x8.0%€11.3m

Price-To-Sales vs Peers: 1MK is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (1.3x).


Price to Sales Ratio vs Industry

How does 1MK's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$823.02m
PHH2 Paul Hartmann
0.3xn/aUS$789.28m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
1MK 1.4xIndustry Avg. 3.7xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1MK is good value based on its Price-To-Sales Ratio (1.4x) compared to the European Medical Equipment industry average (3.5x).


Price to Sales Ratio vs Fair Ratio

What is 1MK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1MK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: 1MK is expensive based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1MK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.16
€2.00
+1,161.0%
50.0%€3.00€1.00n/a2
Nov ’25€0.23
€2.00
+762.1%
50.0%€3.00€1.00n/a2
Oct ’25€0.32
€2.00
+529.9%
50.0%€3.00€1.00n/a2
Sep ’25€0.33
€2.00
+501.5%
50.0%€3.00€1.00n/a2
Aug ’25€0.35
€2.00
+469.0%
50.0%€3.00€1.00n/a2
Jul ’25€0.34
€2.00
+483.1%
50.0%€3.00€1.00n/a2
Jun ’25€0.39
€2.00
+409.6%
50.0%€3.00€1.00n/a2
May ’25€0.36
€2.00
+458.7%
50.0%€3.00€1.00n/a2
Apr ’25€0.38
€1.96
+412.5%
53.5%€3.00€0.91n/a2
Mar ’25€0.41
€1.96
+381.5%
53.5%€3.00€0.91n/a2
Feb ’25€0.42
€1.96
+366.0%
53.5%€3.00€0.91n/a2
Jan ’25€0.44
€1.95
+341.7%
53.8%€3.00€0.90n/a2
Dec ’24€0.39
€1.95
+399.4%
53.8%€3.00€0.90n/a2
Nov ’24€0.42
€1.95
+361.0%
53.8%€3.00€0.90€0.232
Oct ’24€0.59
€1.95
+231.1%
53.8%€3.00€0.90€0.322
Sep ’24€0.54
€1.93
+254.2%
44.9%€3.00€0.88€0.333
Aug ’24€0.59
€1.93
+225.5%
44.9%€3.00€0.88€0.353
Jul ’24€0.63
€1.93
+206.8%
44.9%€3.00€0.88€0.343
Jun ’24€0.65
€1.93
+199.3%
44.4%€3.00€0.90€0.393
May ’24€0.52
€1.94
+273.8%
43.8%€3.00€0.92€0.363
Apr ’24€0.53
€1.93
+268.3%
44.4%€3.00€0.90€0.383
Mar ’24€0.55
€1.93
+249.0%
44.4%€3.00€0.90€0.413
Feb ’24€0.73
€1.93
+166.3%
44.4%€3.00€0.90€0.423
Jan ’24€0.37
€2.45
+562.2%
22.4%€3.00€1.90€0.442
Dec ’23€0.51
€2.45
+381.3%
22.4%€3.00€1.90€0.392
Nov ’23€0.49
€2.45
+404.1%
22.4%€3.00€1.90€0.422

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies